← Back to Clinical Trials
Recruiting Phase 2 NCT06296966
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
Trial Parameters
Condition Dry Eye
Sponsor Vanda Pharmaceuticals
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 40
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-02-29
Completion 2024-07
Interventions
VSJ-110Placebo
Brief Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
Eligibility Criteria
Inclusion Criteria: * Be at least 18 years of age of either gender and any race. * Provide written informed consent and sign the HIPAA form. * Be willing and able to follow all instructions and attend all study visits. Exclusion Criteria: * Use of any of the disallowed medications during the washout and study period.
Related Trials
NCT06841471
Role of Corneal Nerves in Dry Eye Disease
View Trial →
NCT07329712
Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light The
View Trial →
NCT07155070
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (S
View Trial →